Inhibition of the androgen receptor activity by coprinus comatus substances

Nutrition and Cancer

Volumn 63, Issue 8, 2011, Pages 1316-1327

  Dotan, Nesly ^a,b   Wasser, Solomon P ^b,c   Mahajna, Jamal ^a,d  

^a MIGAL GALILEE TECHNOLOGY CENTER   (Israel)

^b UNIVERSITY OF HAIFA   (Israel)

^c M G KHOLODNY INSTITUTE OF BOTANY   (Ukraine)

^d TEL HAI COLLEGE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; ANTINEOPLASTIC AGENT; COPRINUS COMATUS EXTRACT; PLANT EXTRACT; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CELL PROLIFERATION; CELL STRAIN LNCAP; CELL VIABILITY; COPRINUS COMATUS; DRUG ACTIVITY; ENHANCER REGION; ENZYME INHIBITION; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; POINT MUTATION; PROSTATE CANCER; PROTEIN PHOSPHORYLATION;

ANDROGEN ANTAGONISTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHROMATOGRAPHY, LIQUID; COPRINUS; GENES, REPORTER; HUMANS; LUCIFERASES; MALE; PHOSPHORYLATION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 84857314407     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2011.607542     Document Type: Article

References (46)

1. Thompson IM, Tangen CM, Goodman PJ, LuciaMSandKlein EA: Chemoprevention of prostate cancer. J Urol 182, 499-507; discussion, 8, 2009.
2. Jemal A,Murray T,Ward E, Samuels A, Tiwari RC, et al.: Cancer statistics, 2005. CA Cancer J Clin 55, 10-30, 2005.
3. Claessens F, Denayer S, Van Tilborgh N, Kerkhofs S, Helsen C, et al.: Diverse roles of androgen receptor (AR) domains inAR-mediated signaling. Nucl Recept Signal 6, e008, 2008.
4. Suzuki H, Ueda T, Ichikawa T, and Ito H: Androgen receptor involvement in the progression of prostate cancer. Endocr Relat Cancer 10, 209-216, 2003. (Pubitemid 36758650)
5. Brooke GN and Bevan CL: The role of androgen receptor mutations in prostate cancer progression. Curr Genomics 10, 18-25, 2009.
6. Shand RL and Gelmann EP: Molecular biology of prostate-cancer pathogenesis. Curr Opin Urol 16, 123-131, 2006. (Pubitemid 43791779)
7. Culig Z and Bartsch G: Androgen axis in prostate cancer. J Cell Biochem 99, 373-381, 2006. (Pubitemid 44435555)
8. Feldman BJ and Feldman D: The development of androgen-independent prostate cancer. Nat Rev Cancer 1, 34-45, 2001. (Pubitemid 33741879)
9. Balk SP and Knudsen KE: AR, the cell cycle, and prostate cancer. Nucl Recept Signal 6, e001, 2008.
10. Chatterjee B: The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer. Mol Cell Biochem 253, 89-101, 2003. (Pubitemid 37321715)
11. Lindequist U, Niedermeyer TH, and Julich WD: The pharmacological potential of mushrooms. Evid Based Complement Alternat Med 2, 285-299, 2005. (Pubitemid 41258148)
12. Lull C,WichersHJ, and Savelkoul HF: Antiinflammatory and immunomodulating properties of fungal metabolites. Mediators Inflamm 2005, 63-80, 2005. (Pubitemid 41379655)
13. Wasser SP: Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. Appl Microbiol Biotechnol 60, 258-274, 2002.
14. Wasser SP and Weis AL: Therapeutic effects of substances occurring in higher Basidiomycetes mushrooms: a modern perspective. Crit Rev Immunol 19, 65-96, 1999. (Pubitemid 29062102)
15. Lucas EH, Montesano R, Pepper MS, Hafner M, and Sablon E: Tumor inhibitors in Boletus edulis and other holobasidiomycetes. Antibiotics Chemother 7, 1-4, 1957.
16. Yohida TO: A tumor inhibitor in Lampteromyces japonica. PSEBM 3, 676-679, 1962.
17. Roland JF, Chmielewicz ZF, Weiner BA, Gross AM, Boening OP, et al.: Calvacin: a new antitumor agent. Science 132, 1897, 1960.
18. Ikekawa T, Uehara N, Maeda Y, Nakanishi M, and Fukuoka F: Antitumor activity of aqueous extracts of edible mushrooms. Cancer Res 29, 734-735, 1969.
19. Yoshioka Y, Ikekawa T, Noda M, and Fukuoka F: Studies on antitumor activity of some fractions from basidiomyces. I. An antitumor acidic polysaccharide fraction of P. ostreatus (Fr.) Quel. Chem Pharm Bull (Tokyo) 20, 1175-1180, 1972.
20. Yang QY and Jong SC: Medicinal mushrooms in China. Mushr Sci 9, 631-643, 1989.
21. Daba AS and Ezeronye OU: Anticancer effect of polysaccharides isolated from higher basidiomycetes mushrooms. Afr J Biotechnol 2, 672-678, 2003.
22. Mayell M: Maitake extracts and their therapeutic potential. Altern Med Rev 6, 48-60, 2001. (Pubitemid 32194959)
23. Sullivan R, Smith JE, and Rowan NJ: Medicinal mushrooms and cancer therapy: translating a traditional practice into Western medicine. Perspect Biol Med 49, 159-170, 2006.
24. Ruimi N, Rwashdeh H,Wasser S, Konkimalla B, Efferth T, et al.: Daedalea gibbosa substances inhibit LPS-induced expression of iNOS by suppression of NF-kappaB and MAPK activities in RAW264.7 macrophage cells. Int J Mol Med 25, 421-432.
25. YassinM,Wasser SP, andMahajna J: Substances from the medicinal mushroom Daedalea gibbosa inhibit kinase activity of native and T315I mutated Bcr-Abl. Int J Oncol 32, 1197-1204, 2008.
26. Zaidman BZ, Wasser SP, Nevo E, and Mahajna J: Androgen receptordependent and -independent mechanisms mediate Ganoderma lucidum activities in LNCaP prostate cancer cells. Int J Oncol 31, 959-967, 2007.
27. Zaidman BZ, Wasser SP, Nevo E, and Mahajna J: Coprinus comatus and Ganoderma lucidum interfere with androgen receptor function in LNCaP prostate cancer cells.Mol Biol Rep 35, 107-117, 2008. (Pubitemid 351713238)
28. Zaidman BZ, Yassin M, Mahajna J, and Wasser SP: Medicinal mushroom modulators of molecular targets as cancer therapeutics. Appl Microbiol Biotechnol 67, 453-468, 2005. (Pubitemid 40909591)
29. Yassin M, Mahajna J, and Wasser SP: Submerged Cultured mycelium extracts of higher basidiomycetes mushroom selectively inhibit proliferation and induce differeniation of K562 human chronic myelogenous leukemia cells. Int J MedMushr 5, 259-274, 2003.
30. Gu YH and Leonard J: In vitro effects on proliferation, apoptosis and colony inhibition in ER-dependent and ER-independent human breast cancer cells by selected mushroom species. Oncol Rep 15, 417-423, 2006.
31. Hartig PC, Bobseine KL, Britt BH, Cardon MC, Lambright CR, et al.: Development of two androgen receptor assays using adenoviral transduction of MMTV-luc reporter and/or hAR for endocrine screening. Toxicol Sci 66, 82-90, 2002. (Pubitemid 34202031)
32. Wilson VS, Bobseine K, Lambright CR, and Gray LE, Jr.: A novel cell line, MDA-kb2, that stably expresses an androgen- and glucocorticoidresponsive reporter for the detection of hormone receptor agonists and antagonists. Toxicol Sci 66, 69-81, 2002. (Pubitemid 34202030)
33. DeFeo-Jones D, Barnett SF, Fu S, Hancock PJ, Haskell KM, et al.: Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members. Mol Cancer Ther 4, 271-279, 2005. (Pubitemid 40340206)
34. Heinlein CA and Chang C: Androgen receptor (AR) coregulators: an overview. Endocr Rev 23, 175-200, 2002.
35. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100, 57-70, 2000. (Pubitemid 30046295)
36. Bindukumar B, Schwartz SA, Nair MP, Aalinkeel R, Kawinski E, et al.: Prostate-specific antigen modulates the expression of genes involved in prostate tumor growth. Neoplasia 7, 544, 2005. (Pubitemid 40791873)
37. Small EJ and Roach M, III: Prostate-specific antigen in prostate cancer: a case study in the development of a tumor marker to monitor recurrence and assess response. Semin Oncol 29, 264-273, 2002. (Pubitemid 34620443)
38. Rochette-Egly C: Nuclear receptors: integration of multiple signaling pathways through phosphorylation. Cell Signal 15, 355-366, 2003. (Pubitemid 36254908)
39. Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, et al.: HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 6, 517-527, 2004. (Pubitemid 39469987)
40. Zhu Q, Youn H, Tang J, Tawfik O, Dennis K, et al.: Phosphoinositide 3-OH kinase p85alpha and p110beta are essential for androgen receptor transactivation and tumor progression in prostate cancers. Oncogene 27, 4569-4579, 2008.
41. Ghosh PM, Malik S, Bedolla R, and Kreisberg JI: Akt in prostate cancer: possible role in androgen-independence. Curr Drug Metab 4, 487-496, 2003. (Pubitemid 37536869)
42. Gao N, Zhang Z, Jiang BH and Shi X: Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem Biophys Res Commun 310, 1124-1132, 2003. (Pubitemid 37237653)
43. Aziz MH, Nihal M, Fu VX, Jarrard DF, and Ahmad N: Resveratrol-caused apoptosis of human prostate carcinoma LNCaP cells is mediated via modulation of phosphatidylinositol 3'-kinase/Akt pathway and Bcl-2 family proteins. Mol Cancer Ther 5, 1335-1341, 2006. (Pubitemid 43881327)
44. Benitez DA, Pozo-Guisado E, Clementi M, Castellon E, and Fernandez- Salguero PM:Non-genomic action of resveratrol on androgen and oestrogen receptors in prostate cancer: modulation of the phosphoinositide 3-kinase pathway. Br J Cancer 96, 1595-1604, 2007. (Pubitemid 46762955)
45. Shankar S and Srivastava RK: Involvement of Bcl-2 family members, phosphatidylinositol 3'-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced apoptosis in prostate cancer. Int J Oncol 30, 905-918, 2007.
46. Dotan N, Wasser SP, and Mahajna J: The culinary medical mushroom Coprinus comatus as a natural antiandrogenic modulator. Integr Cancer Ther 10, 148-159, 2010.